N/A N=36 Investigation of the Effect of Short-term Orthokeratology With Increased Compression Factor on Ocular Parameters
Myopic Progression
Primary: Changes in Spherical Equivalent Refraction — 2.31; 2.52 D
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=36 Determining the Benefits of Improving Communication in BPAP/CPAP Users
Positive-Pressure Respiration · Communication
Primary: Accuracy of Single Word Selection (Proportion of Right Words From Total) — 0.61; 0.35 proportion of right words
Phase 3 N=301 Treatment of Patients With Nocturia
Nocturia
Primary: Change in Mean Number of Nocturic Episodes/Night — -1.3; -1.2 nocturic episodes per night
Phase 2 N=55 Trial for Locally Advanced Breast Cancer Using Vorinostat Plus Chemotherapy
Breast Cancer
Primary: Recommended Phase II Dose of Vorinostat in Combination With Weekly Paclitaxel/Trastuzumab — 300; 300 mg
N/A N=2,140 Project CLEAR - Changing Lives by Eradicating Antibiotic Resistance
Methicillin-resistant Staphylococcus Aureus
Primary: Time to MRSA Infection — 67; 98; 68; 98 Participants — p=0.026
N/A N=54 Fluorine F 18 Sodium Fluoride PET/CT and Whole Body and Axial MRI in Finding Metastases in Patients With Recurrent Prostate Cancer
Recurrent Prostate Cancer
Primary: Number of Eligible Patients With Positive CT Scan/Bone Scan, MRI and PET Scan. — 0; 0; 12; 17 Participants
Phase 3 N=296 A Clinical Endpoint Bioequivalence Study to Assess Efficacy and Safety of Ivermectin 0.5% Lotion in the Treatment of Head Lice
Head Lice
Primary: The Proportion of Index Subjects Who Are Lice Free at Day 15 — 106; 98; 7 Participants
Phase 1 N=72 A Single Dose-escalation Study of Cytisine in Adult Smokers
Smoking Cessation
Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs, and TEAEs Leading to Study Discontinuation — 5; 2; 1; 4 participants
Phase 2 N=48 Convalescent Plasma in the Treatment of COVID 19
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) · COVID · Coronavirus
Primary: Mortality — 19 Participants
Phase 2 N=82 Effects of Topiramate on Adolescent Alcohol Use: Efficacy and Mechanisms
Alcohol Drinking
Primary: Alcohol Use — 29.59; 27.08 Percent of days
N/A N=50 A Fixed Triple Combination Cream for Solar Lentigines Associated to Cryotherapy
Solar Lentigines
Primary: Solar Lentigines Count — 25.7; 26.0; 8.0; 11.0 Number of solar lentigines
Phase 3 N=376 Study of COV795 in Subjects With Osteoarthritis or Chronic Low Back Pain
Osteoarthritis · Low Back Pain
Primary: Summary of Adverse Events (AEs) — 235; 17; 200; 4 Participants
Phase 4 N=50 Efficacy and Safety of Drug Eluting Beads TACE in Treatment of HCC in Egyptian Patients
HepatoCellular Carcinoma
Primary: Number of Participants With Complete Response — 23; 22 Participants
Phase 2 N=45 Bortezomib, Thalidomide, and Dexamethasone After Melphalan and Stem Cell Transplant in Treating Patients With Stage I-III Multiple Myeloma
Multiple Myeloma and Plasma Cell Neoplasm · Neurotoxicity
Primary: Number of Participants With Adverse Events — 1; 13; 2; 1 Participants
Phase 2 N=97 Study of Lenvatinib in Children and Adolescents With Refractory or Relapsed Solid Malignancies and Young Adults With Osteosarcoma
Tumors · Solid Malignant Tumors · Osteosarcoma
Primary: Cohort 1: Recommended Dose (RD) of Lenvatinib — 14 milligram per square meter (mg/m^2)